Medicure Inc. (OTCMKTS:MCUJF) Short Interest Down 66.7% in August
Medicure Inc. (OTCMKTS:MCUJF) Short Interest Down 66.7% in August
Medicure Inc, a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market in Canada and the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction.Medicure Inc. (OTCMKTS:MCUJF – Get Rating) was the target of a large decline in short interest in the month of August. As of August 15th, there was short interest totalling 100 shares, a decline of 66.7% from the July 31st total of 300 shares. Based on an average trading volume of 16,600 shares, the days-to-cover ratio is presently 0.0 days.
Medicure Inc.（OTCMKTS: MCUJF — 获取评级）是8月份空头利率大幅下降的目标。截至8月15日，空头利息总额为100股，较7月31日的300股总额下降了66.7％。根据16,600股的平均交易量，目前的回报天数为0.0天。
Medicure Trading Down 6.2 %
Medicure交易下跌6.2％
Shares of MCUJF stock opened at $0.79 on Friday. The company's fifty day simple moving average is $0.84 and its two-hundred day simple moving average is $0.84. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.61 and a quick ratio of 1.18. Medicure has a 1 year low of $0.64 and a 1 year high of $1.10. The stock has a market capitalization of $8.10 million, a price-to-earnings ratio of 14.04 and a beta of 0.83.
周五，MCUJF股票开盘价为0.79美元。该公司的五十天简单移动平均线为0.84美元，其两百天简单移动平均线为0.84美元。该公司的债务与权益比率为0.04，流动比率为1.61，速动比率为1.18。Medicure的1年低点为0.64美元，为1年来的最高水平，为1.10美元。该股票的市值为810万美元，市盈率为14.04，beta值为0.83。
Medicure (OTCMKTS:MCUJF – Get Rating) last issued its earnings results on Monday, May 30th. The company reported $0.04 earnings per share (EPS) for the quarter. Medicure had a net margin of 3.40% and a return on equity of 4.28%. The business had revenue of $4.51 million for the quarter.
Medicure（OTCMKTS: MCUJF — 获取评级）最后一次发布财报是在5月30日星期一。该公司报告本季度每股收益（EPS）为0.04美元。Medicure的净利润率为3.40％，股本回报率为4.28％。该业务本季度的收入为451万美元。
About Medicure
关于 Medicure
Medicure Inc, a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market in Canada and the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction.
Medicure Inc是一家生物制药公司，从事加拿大和美国心血管市场人体疗法的研究、开发和商业化。该公司销售和分销 EGRANSTAT 注射剂，这是一种糖蛋白 GP iib/IIIa 受体拮抗剂，用于治疗急性冠脉综合征，包括不稳定型心绞痛和非 Q 波心肌梗死。
Featured Articles
精选文章
- Get a free copy of the StockNews.com research report on Medicure (MCUJF)
- Should AbbVie Inc. Have a Place in Your Dividend Portfolio?
- Is PayPal A Buy After Post-Earnings Price Jump?
- Williams-Sonoma's High-End Consumers Are Still Spending
- Snowflake Stock Soars On Strong Results
- ShockWave Stuns With 40% Post-Earnings Price Move: Is It A Buy?
- 免费获取 StockNews.com 关于 Medicure 的研究报告 (MCUJF) 的副本
- AbbVie Inc. 应该在你的股息投资组合中占有一席之地吗？
- 盈利后价格上涨后，PayPal是买入吗？
- 威廉姆斯-索诺玛的高端消费者仍在消费
- Snowflake 股票因业绩强劲而飙升
- ShockWave 在财报公布后价格变动了 40%，令人震惊：这是买入吗？
Receive News & Ratings for Medicure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicure and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Medicure Daily 的新闻和收视率 -在下面输入您的电子邮件地址，以通过Marketbeat.com的免费每日电子邮件时事通讯接收Medicure及相关公司最新新闻和分析师评级的简明每日摘要。